Protein - based drugs are big business, yet biotech and
pharma companies often struggle to turn proteins into medicines.
Not exact matches
But the initiative comes with another huge financial prize for firms that successfully win FDA approval for these niche therapies: a priority review voucher that can be used to slash the regulatory period for a different experimental specialty treatment being developed by a drug maker or, more
often, sold for potentially hundreds of millions of dollars to another
pharma company.
In periods of rising volatility,
pharma companies are
often especially vulnerable because of investors are paying big prices today for therapies expected to pay off over a long horizon.
Large
companies (Big
Pharma) spend considerable amounts on advertising and distribution, and
often have large sales forces that promote their drugs to physicians to convince them to prescribe the drug.
Once they are out of university, «we are more likely to recruit those with work experience in the small - molecule field,
often from
pharma companies,» she says.
Up to this point, Harack explains, start - up biotech
companies in Canada have
often looked to the U.S. and Europe, or to larger
pharma companies in Canada, to recruit their staff.